March 20, 2023
The study, which was conducted at UNC-Chapel Hill between 2016 and 2022, concluded that metformin use did not reduce risks for adverse neonatal outcomes in pregnancies with type 2 diabetes. The study findings were reported at the annual meeting of the Society for Maternal Fetal Medicine in February.
November 16, 2022
11-year-old Izzy Dixon is sharing her story on how she is managing her Type 1 diabetes at a young age. Hear her story and how experts at UNC Children's guided her on her journey to wellness.
September 28, 2022
This nationwide clinical trial funded through the National Institutes of Health including participation from patients at the UNC Diabetes Center, led by John Buse, MD, PhD.
September 22, 2022
The national GRADE study, with leadership and participation from UNC School of Medicine's John Buse, MD, PhD, and Sue Kirkman, MD, found that two of four common type 2 diabetes treatments -- glargine and liraglutide -- worked better than the other drugs, sitagliptin and glimepiride, to maintain blood glucose levels.
April 28, 2022
Katrina Donahue, MD, MPH, and Laura Young, MD, PhD, received a grant from the National Institute of Health to increase uptake of diabetes self-management education. The study will focus on two factors: provider and diabetes care and education specialist engagement with patients, and patient peer support.
March 17, 2022
A qualitative study led by UNC School of Medicine student Lily Hale details what primary care providers and endocrine specialty clinicians reported about their patients’ self-management of diabetes during the pandemic and the effectiveness of providers’ support.
February 28, 2022
UNC Peers for Progress is funded as the Community, Family, and Peer Support Core of the University of Michigan Center for Diabetes Translational Research. UNC-Chapel Hill researchers are eligible to apply for Pilot and Feasibility awards of up to $50,000 through the Michigan Center.
June 17, 2021
Led by John Buse, MD, PhD, and Anna Kahkoska, MD, PhD, this analysis showed that GLP1-RA and SGLT2i medication use for type 2 diabetes of hospitalized COVID-19 patients was associated with lower odds of mortality and other adverse outcomes.
April 28, 2021
UNC's NC TraCS and the Center for Advanced Self-powered Systems of Integrated Sensors and Technologies (ASSIST) at NC State is seeking highly innovative proposals that address high-impact unmet clinical needs using NC State’s ASSIST-developed technologies. The goal of this Special Emphasis is to match UNC providers’ expertise of clinical challenges and unmet needs, with engineering faculty at ASSIST seeking to develop novel technology applications.
February 23, 2021
Led by Klara Klein, MD, PhD, the study showed that treatment with 800mg of TTP399 demonstrated statistically significant reductions in HbA1c and clinically relevant reduction in the frequency of severe or symptomatic hypoglycemia.
November 4, 2020
Published in The Lancet Diabetes & Endocrinology, a paper co-authored by seven leading diabetes experts in Europe and the United Sates, including UNC’s John Buse, MD, PhD, warns against medical inertia that prevents physicians from helping patients with type 2 diabetes and cardiorenal disease.
August 20, 2020
Laura Young, MD, PhD, and Katherine Bergamo, FNP-C, are local principal investigators for two papers recently published in the Journal of American Medicine Association.